Abbott (NYSE:ABT) said today that it enrolled the first patient in a trial evaluating the short-term use of blood thinning drugs, called dual antiplatelet therapy, after implantation of the company’s Xience everolimus-eluting coronary stent.
The 2,000-patient study is slated to assess if three months of DAPT is non-inferior to the current standard of 12 months for patients at high risk of bleeding.
Get the full story at our sister site, Drug Delivery Business News.
